With these recent molecular insights into the central role of the BRAF mutation in LCH pathogenesis, vemurafenib has emerged as a therapeutic option for children grappling with high‐risk multisystemic disease that proves refractory to conventional treatments or experiences recurrent relapses. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.